Juno Therapeutics (JUNO) has risen sharply, recording gains of 5.52% in the past 4 weeks. However, the stock has corrected -0.33% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 6.09% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 1.13% and the 50-Day Moving Average is 2.81%.The 200 Day SMA reached 17.59%
Juno Therapeutics (NASDAQ:JUNO): After opening at $30.12, the stock dipped to an intraday low of $29.65 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $30.4899 and the buying power remained strong till the end. The stock closed at $30.01 for the day, a gain of 0.07% for the day session. The total traded volume was 1,456,580. The stocks close on the previous trading day was $30.01.
Juno Therapeutics (JUNO) : The highest short term price target forecast on Juno Therapeutics (JUNO) is $61 and the lowest target price is $41. A total of 8 equity analysts are currently covering the company. The average price of all the analysts is $48.75 with a standard deviation of $6.04.
Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Junos product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Junos other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171), JCAR020: MUC-16 / IL-12, ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML, myelodysplasic syndrome and chronic myeloid leukemia.